Chimeric transcripts observed in non-canonical FGFR2 fusions with partner genes' breakpoint located in intergenic region in intrahepatic cholangiocarcinoma

Gupta, 2017, Epidemiology and risk factors: intrahepatic cholangiocarcinoma, Hepatobiliary Surg Nutr, 101, 10.21037/hbsn.2017.01.02 Li, 2020, Functions of FGFR2 corrupted by translocations in intrahepatic cholangiocarcinoma, Cytokine Growth Factor Rev, 56, 10.1016/j.cytogfr.2019.12.005 Kongpetch, 2020, Lack of targetable FGFR2 fusions in endemic fluke-associated cholangiocarcinoma, JCO Glob Oncol, 6, 628, 10.1200/GO.20.00030 De Luca, 2020, FGFR fusions in cancer: from diagnostic approaches to therapeutic intervention, Int J Mol Sci, 21, 6856, 10.3390/ijms21186856 Parker, 2014, Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumours, J Pathol, 232, 4, 10.1002/path.4297 Gallo, 2015, Functions of fibroblast growth factor receptors in cancer defined by novel translocations and mutations, Cytokine Growth Factor Rev, 26, 425, 10.1016/j.cytogfr.2015.03.003 Parker, 2013, The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma, J Clin Invest, 123, 855 Javle, 2018, Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma, J Clin Oncol, 36, 276, 10.1200/JCO.2017.75.5009 Mazzaferro, 2019, Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma, Br J Cancer, 120, 165, 10.1038/s41416-018-0334-0 Wang, 2017, Recurrent fusion genes in leukemia: an attractive target for diagnosis and treatment, Curr Genomics, 18, 378, 10.2174/1389202918666170329110349 Wang, 2015, The structural characterization of tumor fusion genes and proteins, Comput Math Methods Med, 10.1155/2015/912742 Yun, 2020, Dysregulation of cancer genes by recurrent intergenic fusions, Genome Biol, 21, 166, 10.1186/s13059-020-02076-2 Li, 2020, Intergenic Breakpoints Identified by DNA sequencing confound targetable kinase fusion detection in NSCLC, J Thorac Oncol, 15, 1223, 10.1016/j.jtho.2020.02.023 Bruno, 2020, Next generation sequencing for gene fusion analysis in lung cancer: a literature review, Diagnostics, 10, 521, 10.3390/diagnostics10080521 Dobin, 2016, Optimizing RNA-Seq mapping with STAR, Methods Mol Biol, 1415, 245, 10.1007/978-1-4939-3572-7_13 Arai, 2014, Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma, Hepatology, 59, 1427, 10.1002/hep.26890 Graham, 2014, Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma, Hum Pathol, 45, 1630, 10.1016/j.humpath.2014.03.014 Mahipal, 2019, FGFR2 genomic aberrations: achilles heel in the management of advanced cholangiocarcinoma, Cancer Treat Rev, 78, 1, 10.1016/j.ctrv.2019.06.003 Abou-Alfa, 2020, Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study, Lancet Oncol, 21, 671, 10.1016/S1470-2045(20)30109-1 Maruki, 2020, Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study), J Gastroenterol Benayed, 2019, High yield of RNA Sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration detected by DNA sequencing and low tumor mutation burden, Clin Cancer Res, 25, 4712, 10.1158/1078-0432.CCR-19-0225 Davies, 2019, Wake up and smell the fusions: single-modality molecular testing misses drivers, Clin Cancer Res, 25, 4586, 10.1158/1078-0432.CCR-19-1361 Heyer, 2019, Diagnosis of fusion genes using targeted RNA sequencing, Nat Commun, 10, 1388, 10.1038/s41467-019-09374-9 Cohen, 2020, Optimizing mutation and fusion detection in NSCLC by sequential DNA and RNA sequencing, J Thorac Oncol, 15, 1000, 10.1016/j.jtho.2020.01.019 Li, 2021, Potential unreliability of uncommon ALK, ROS1, and RET genomic breakpoints in predicting the efficacy of targeted therapy in NSCLC, J Thorac Oncol, 16, 404, 10.1016/j.jtho.2020.10.156 Lv, 2020, A Novel intergenic LSM14A-RET fusion variant in a patient with lung adenocarcinoma, J Thorac Oncol, 15, e52, 10.1016/j.jtho.2019.11.025 Zhang, 2020, A Novel Linc00308/D21S2088E intergenic region ALK fusion and its enduring clinical responses to crizotinib, J Thorac Oncol, 15, 1073, 10.1016/j.jtho.2020.03.009 Fei, 2019, A novel intergenic region between CENPA and DPYSL5-ALK Exon 20 fusion variant responding to crizotinib treatment in a patient with lung adenocarcinoma, J Thorac Oncol, 14, e191, 10.1016/j.jtho.2019.04.012 Ward, 2010, The pathobiology of splicing, J Pathol, 220, 152, 10.1002/path.2649 Cha, 2009, Aberrant receptor internalization and enhanced FRS2-dependent signaling contribute to the transforming activity of the fibroblast growth factor receptor 2 IIIb C3 isoform, J Biol Chem, 284, 6227, 10.1074/jbc.M803998200 Wu, 2013, Identification of targetable FGFR gene fusions in diverse cancers, Cancer Discov, 3, 636, 10.1158/2159-8290.CD-13-0050 Brasher, 2000, The structure of mouse HP1 suggests a unique mode of single peptide recognition by the shadow chromo domain dimer, EMBO J, 19, 1587, 10.1093/emboj/19.7.1587 Mendez, 2013, Heterochromatin Protein 1a (HP1a) partner specificity is determined by critical amino acids in the chromo shadow domain and C-terminal extension, J Biol Chem, 288, 22315, 10.1074/jbc.M113.468413 Machida, 2018, Structural basis of heterochromatin formation by human HP1, Mol Cell, 69, 385, 10.1016/j.molcel.2017.12.011